Thrombin inhibitor argatroban modulates bone marrow stromal cells behaviors and promotes osteogenesis through canonical Wnt signaling

•This study explored that argatroban, a clinically approved anti-coagulation drug, inhibits bone marrow stromal cells proliferation and migration capabilities, and, however, drives cells osteogenesis differentiation.•In addition, molecular analysis reveals that argatroban promotes β-catenin nuclear translocation and lead to an increase of osteogenesis through activating canonical Wnt signaling.•Collectively, this study unveils argatroban or other anti-coagulation drugs effects from the knowledge of employing bone hemostasis into bone metabolism and contributes to clinical orthopedic and maxillofacial bone regeneration.